Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cDC1 Vaccine with Trastuzumab or Nivolumab in Breast Cancer Leptomeningeal Disease
NCT07694986Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
A Phase 2 trial of cDC1 vaccine in breast cancer, leptomeningeal disease (LMD), sponsored by Moffitt Cancer Center. Started Aug 2026; status: recruiting.
02
Drugs
cDC1 vaccine
03
Conditions
breast cancerleptomeningeal disease (LMD)
Beyond the preview
Go deeper on NCT07694986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694986.